文献速递垂体与肾上腺疾病

COVID-19期间肾上腺功能不全患者症状与并发症的回顾性病例对照研究

Adrenal Insufficiency at the Time of COVID-19: A Retrospective Study in Patients Referring to a Tertiary Center.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究为回顾性病例对照研究,纳入意大利伦巴第地区279例原发性和继发性肾上腺功能不全(AI)患者及112例对照(无激素异常的良性垂体病变患者)。通过电话标准化问卷收集2020年2月至4月COVID-19可疑症状及后果,发现AI患者与对照组在症状性感染(24% vs 22.3%,P=0.79)及高度可疑COVID-19症状(两组均为12.5%)发生率上无显著差异,无患者需住院或发生肾上腺危象。结论提示经充分治疗和培训的AI患者似乎与对照组呈现相似的COVID-19可疑症状发生率和疾病严重程度。

要点

  • 经充分治疗和压力剂量培训的AI患者,COVID-19可疑症状发生率与对照相似。
  • 两组均无患者因COVID-19住院,也无肾上腺危象报告。
  • 鼻咽拭子检测数量有限(n=12),限制了对确切感染率的结论。

核心结论

  • 经充分治疗和培训的肾上腺功能不全患者,其COVID-19可疑症状发生率和疾病严重程度似乎与对照组相同。

研究设计与样本

  • 回顾性病例对照研究,纳入279例原发性和继发性肾上腺功能不全患者及112例对照(无激素异常的良性垂体病变患者),所有患者均在意大利伦巴第地区进行主动随访。

主要发现

  • 2020年2月至4月,症状性患者(至少1个病毒感染症状)比例在AI组为24%、对照组为22.3%(P=0.79)。
  • 高度可疑COVID-19症状(至少2个包括发热和/或咳嗽)在AI组和对照组均为12.5%。
  • 无患者需要住院,无肾上腺危象报告。
  • 鼻咽拭子检测仅12例(AI组2例阳性,对照组0例,P=0.52)。

临床怎么用

  • 对于经充分治疗和压力剂量培训的肾上腺功能不全患者,在COVID-19疫情期间可能无需过度担忧其感染风险显著增加。

局限性

  • 鼻咽拭子检测数量有限(n=12),限制了对确切感染率的结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Coronavirus disease 2019 (COVID-19) represents a global health emergency, and infected patients with chronic diseases often present with a severe impairment. Adrenal insufficiency (AI) is supposed to be associated with an increased infection risk, which could trigger an adrenal crisis. OBJECTIVE: Our primary aim was to evaluate the incidence of COVID-19 symptoms and complications in AI patients. DESIGN AND SETTING: We conducted a retrospective case-control study. All patients were on active follow-up and lived in Lombardy, Italy, one of the most affected areas. PATIENTS: We enrolled 279 patients with primary and secondary AI and 112 controls (patients with benign pituitary lesions without hormonal alterations). All AI patients had been previously trained to modify their replacement therapy on stress doses. INTERVENTION: By administering a standardized questionnaire by phone, we collected data on COVID-19 suggestive symptoms and consequences. RESULTS: In February through April 2020, the prevalence of symptomatic patients (complaining at least 1 symptom of viral infection) was similar between the 2 groups (24% in AI and 22.3% in controls, P = 0.79). Highly suggestive COVID-19 symptoms (at least 2 including fever and/or cough) also occurred equally in AI and controls (12.5% in both groups). No patient required hospitalization and no adrenal crisis was reported. Few nasopharyngeal swabs were performed (n = 12), as indicated by sanitary regulations, limiting conclusions on the exact infection rate (2 positive results in AI and none in controls, P = 0.52). CONCLUSIONS: AI patients who are adequately treated and trained seem to display the same incidence of COVID-19-suggestive symptoms and disease severity as controls.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Carosi G, Morelli V, Del Sindaco G, et al. Adrenal Insufficiency at the Time of COVID-19: A Retrospective Study in Patients Referring to a Tertiary Center. J Clin Endocrinol Metab. 2021. PMID: 33107576. doi:10.1210/clinem/dgaa793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。